Close Menu

schizophrenia

Using a deep learning approach to study mutations in target sites of RNA-binding proteins, researchers identified DDHD2 as a candidate schizophrenia risk gene.

In PLOS this week: potential neuropsychiatric drug targets identified, analysis of foodborne pathogen genome, and more.

In PLOS this week: phenome-wide association study of psychiatric disorder polygenic risk scores, CNV patterns in rhesus macaques, and more.

The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.

In Nature this week: missense variant linked to decreased height among Peruvians, genetic basis of sex-biased vulnerability to certain disorders, and more.

The analysis of a hippocampus cell layer uncovered genetic loci associated with schizophrenia risk, including two that may represent drug targets.

Investigators tracked down a methylation signature in blood that corresponded with features found in postmortem brain samples from schizophrenia cases.

In Science this week: genetic mutation linked to schizophrenia among South African Xhosas, engineering the bee microbiome to address parasite and virus, and more.

An analysis of cases and controls from South Africa's Xhosa population pointed to private, damaging mutations in genes expressed in the brain.

While de novo mutations appeared to make relatively modest contributions to schizophrenia risk, they recurrently affected evolutionarily conserved genes.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.